- NYSE: MRX*
- Sector: Healthcare
- Industry: Pharmaceuticals
Acquired by Valeant Pharmaceuticals International, Inc.
Medicis Pharmaceutical Corporation, a specialty pharmaceutical company, engages in the development and marketing of various products for the treatment of dermatological and aesthetic conditions in the United States and Canada. It provides acne-related dermatological products, including SOLODYN for the treatment of inflammatory lesions of non-nodular acne vulgaris in patients 12 years of age or older; and ZIANA Gel to treat acne vulgaris in patients 12 years and older. The company also offers non-acne dermatological products comprising DYSPORT, an injectable botulinum toxin type A formulation for the temporary improvement in the appearance of glabellar lines in adults younger than 65 years of age; LOPROX; PERLANE and RESTYLANE for the correction of facial wrinkles and folds, such as nasolabial folds; VANOS cream for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in patients 12 years of age or older; and ZYCLARA Cream for the treatment of clinically typical visible or palpable actinic keratoses of the full face or balding scalp in immunocompetent adults, as well as for treating external genital warts and perianal warts in patients 12 years or older. In addition, it provides non-dermatological products consisting of AMMONUL and BUPHENYL powder and tablets for the treatment of urea cycle disorders. The company sells its products to wholesale pharmaceutical distributors and retail pharmacy chains. It has strategic collaborations with Lupin Limited; Anacor Pharmaceuticals, Inc.; Revance Therapeutics, Inc.; Hyperion Therapeutics, Inc.; Perrigo Israel Pharmaceuticals Ltd.; and Impax Laboratories, Inc. The company was founded in 1987 and is headquartered in Scottsdale, Arizona. As of December 11, 2012, Medicis Pharmaceutical Corporation operates as a subsidiary of Valeant Pharmaceuticals International, Inc.